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Project 1: Investigating the role of FAM198b in angiogenesis, 
tumourgenesis and wound repair 
 
Introduction 
Family with sequence similarity 198, member B (FAM198b), which is also known as C4orf18, 
ENED, AD021, AD036, TCPD2512, DKFZp434L142 and FLJ38155, has been identified as being 
expressed in human umbilical cord endothelial cells (HUVECs) (unpublished data). 
Additionally microarray data published by Sun et al. (2005) identified the expression of 
FAM198b as being increased in human microvascular endothelial cells in a 3-D microcarrier 
bead based angiogenesis system. Currently the structure and function of FAM198b is not 
known, but its presence in endothelial cells and upregulation in bead based angiogenesis 
assays (sprouting, branching, and capillary network formation) could indicate a potential role 
in angiogenesis. 
Currently, little is known about the structure or function of FAM198b. However some 
databases have compiled information from whole genome microarray studies, from which 
the expression of FAM198b within different tissues can be explored (figure 1). Many of these 
studies have been carried out in cancer cell lines or cells from mammalian animal models, 
but can shed some light on the expression of the human equivalent of FAM198b. For 
example FAM198b is consistently shown to be under expressed in tissues associated with 
the liver.  
Microarray data sets can be compiled and analysed to produce genes maps, which can 
predict interactions between genes. One such gene map analysed by Hecker et al. (2009) 
 2 
predicted that FAM198b could be under the transcriptional control of the TATA-binding 
protein; Transcription Factor II D and the Hepatocyte Nuclear Factor 1 homeobox A (HNF-
1A). Whilst these interactions have not been validated it is interesting that the up-regulation 
of HNF-1A has been linked to the down-regulation of FAM198b after the onset of anti-
rheumatic therapy. HNF-1A is known to be predominantly expressed in the liver, which 
would be consistent with observation of FAM198b being down-regulated in liver. With 
respect to angiogenesis it is also interesting that FAM198b was down-regulated after the 
onset of anti-rheumatic therapy. As angiogenesis can be stimulated by inflammation, this 
data could indicate that FAM198b is a pro-angiogenic factor. The microarray data does not 
however address the fact that FAM198b has been predicted to have three splice variants, 
which would produce two different proteins (figure 2). Additionally the microarray data does 
not differentiate between the different expressions of different splice variants. It is possible 
that the expression of the FAM198b splice variants could be preferentially expressed in 
different tissues.  
 
 
Figure 1: Compilation of microarray studies where FAM198b expression is modified 
The number of published studies utilising microarray data, which have found FAM198b to be over expressed 
has been depicted in red. The studies which suggest that FAM198b is under expressed have been depicted in 
blue (Diagram obtained from European Bioinformatics Institute, 2011). 
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Figure 2: A diagrammatic representation of the three splice variants predicted to be expressed by FAM198b. 
The regions of the FAM198b gene thought to be exons are depicted by boxes, whereas the introns are depicted 
by black lines. The exons shared by the three variants are shown as grey, whereas the differing regions are 
coloured. 
Splice Variant 1 (SV1) - SV1 shares an alternative exon in the five prime untranslated region (5’ UTR) with the 
third splice variant. SV1 also contains a unique exon, which is not expressed in the second or third variants. The 
forth exon in SV1 also thought to be a shortened version of the third exon thought to be present in the other 
two variants. 
Splice Variant 2 (SV2) - SV2 is thought to contain a unique exon in the three prime region of its transcript. 
Splice Variant 3 (SV3) - SV3 would encode a protein identical to SV2 despite sharing a 5’ UTR with SV1. 
(Original Diagram). 
 
It is currently unknown whether the first and second isoforms of the FAM198b 
protein have similar or different functions. But it is possible to determine the degree to 
which FAM198b has been conserved over time. This is possible by aligning the protein 
sequences of isoform 1 (SV1) and isoform 2 (SV2 and 3) to their homologous proteins in 
different species. This information can give insights into the importance of the protein within 
the cell. A protein which is essential to the viability of an organism would have a highly 
conserved sequence, whereas a redundant protein might not be highly conserved. Groups of 
amino acid sequences which are more highly conserved than others within a protein can also 
indicate which regions of a protein are more important to its function. This is particularly 
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true for angiogenesis, largely due to the high level of conservation among vertebrates of 
signalling factors involved in angiogenesis (Adams and Eichmann, 2010). 
FAM198b-like proteins are present in a wide variety of organisms and are relatively 
highly conserved when compared to the sequence of FAM198b in man. The key difference 
between FAM198b isoform 1 and 2 stems from the alternative exon in SV1, the protein 
sequences for this region in both isoform 1 and 2 are shown in figure 3. The unique 
sequence encoded in isoform 1 has only been found in the transcripts of higher primates 
such as the chimpanzee. Whereas the alternative sequence found in isoform 2 has been 
conserved in many different phylogenies. The knowledge that FAM198b isoform 1 is present 
in chimpanzee provides evidence that the protein is probably expressed. However it is likely 
that isoform 2 could have a more significant role in the viability of an organism, as it is 
conserved in many phylogenies. This does not exclude the possibility that isoform 1 could 
play an important role in higher primates and man. 
The analysis of the protein sequence can also provide information into the function 
of FAM198b using bioinformatics. Clark et al. (2003) listed FAM198b in their supplementary 
information as being a possible transmembrane protein in the golgi apparatus. This was 
predicting using several approaches including the prediction of signal proteins, hydrophobic 
properties of signal sequences and searching for sequence similarities to known receptors 
and ligands. 
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Figure 3: Protein sequence alignments for FAM198b and FAM198b-like proteins. 
The amino acids which are conserved in all the above species are represented in green. The amino acids 
conserved in multiple species except zebra fish are represented in yellow, whereas the amino acids which were 
conserved but not humans are represented in blue (Original diagram). 
 
Angiogenesis 
Angiogenesis is the process of developing new blood vessels from existing vessels. The 
process of developing new vessels has an essential role in wound healing and normal 
development. However angiogenesis can also be a precipitating factor in the etiology of 
many diseases such as cancer. Endothelial cells are a significant contributor to these 
processes. Despite their low turn over, endothelial cells retain the potential for high levels of 
proliferation in the adult, which when activated can contribute to regenerative or 
pathological processes. Due to the connection between the vasculature and cancer, blood 
vessels in the tumour have been the target of anti-cancer therapies. These strategies are not 
only designed to inhibit tumour growth, but also cancer cell dissemination (Riasu, 1997; 
Carmeliet 2003; Ferrara and Kerbel 2005; Martin and Murray, 2009; Arroyo and Iruela-
Arispe, 2010). 
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Angiogenesis is complicated process involving many mechanisms. So far four types of 
guidance molecules have been shown to be involved in vascular development. It is 
interesting to note that these molecules are also involved in neuronal guidance. The Netrins, 
Ephrins, Semaphorins and Slits act to attract or repel migrating endothelial cells. Different 
combinations of attractive and repulsive signals are expressed in the surrounding tissue, 
which aids in the navigation of developing vessels through “tissue corridors” (Martin and 
Murray, 2009; Arroyo and Iruela-Arispe, 2010). 
In adults capillary sprouting is one of the two known mechanisms of forming new 
blood vessels. The vascular endothelial growth factor (VEGF) pathway is one of the most 
significant regulators of capillary formation. Many of the biological functions in the VEGF 
pathway are induced by VEGF and are transduced by vascular endothelial growth factor 
receptor (VEGFR) 1 and 2. Gradients of soluble VEGFR1 are able to modulate the activation 
of VEGFR2. This enables the fine tuning of the events which guide endothelial cells during 
capillary sprouting (Martin and Murray, 2009; Arroyo and Iruela-Arispe, 2010). 
The endothelial cells responsible for the initial stages of vascular development and 
capillary sprouting differentiate into tip cells once stimulated (figure 4). Tip cell formation 
and differentiation is controlled by the Notch pathway. These specialised endothelial cells 
respond to gradients of VEGF and other molecules, at which point they proceed to invade 
the extracellular matrix (ECM). Tip cells break through the basement membrane, interstitial 
matrix, and the fibrin matrix by using proteases such as matrix metalloproteinase’s. Tip cells 
are capable of extending long filopodial protrusions, which control the guidance of migration 
and react to external stimuli. Only a small proportion of endothelial cells acquire the 
characteristics associated with tip cells. The majority of the endothelial cells remain in place 
to maintain the functional integrity of the vessel. The endothelial cells that remain behind 
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the tip cell proliferate, elongate and form a lumen as the tip cell migrates towards attractive 
signals. Once the capillary sprout has formed a lumen and fuses with a blood vessel to allow 
blood flow, the endothelial cells return to their quiescent state (Adams and Eichmann, 2010; 
Arroyo and Iruela-Arispe, 2010; Carmeliet and Jian, 2011). 
 
Figure 4: Tip cell formation, angiogenic sprouting and blood vessel growth. 
When endothelial cells in mature blood vessels are activated in response to angiogenic stimuli they form tip 
cells. The tip cell will start to migrate once has broken through the basement membrane and has lost contact 
with surrounding mural cells. These tip cells are followed by proliferating endothelial cells, which assemble to 
form capillary-like sprouts. The new sprouts will eventually fuse with themselves or existing blood vessels to 
establish blood flow. (Original diagram compiled using information from Carmeliet, 2003; Adams and 
Eichmann, 2010). 
 
Capillary sprouting is a significant contributor to angiogenesis, especially in areas like 
the brain foetal brain and areas not containing angioblasts. However Intussusceptive (non-
sprouting) angiogenesis is the predominant mechanism in the lung, where endogenous 
endothelial precursors contribute to angiogenesis. Intussusception can be caused by the 
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proliferation of endothelial cells within a vessel to produce a wide lumen. This enlarged 
lumen can be split by fusion of capillaries and transcapillary pillars (the development 
formation of columns by thickened endothelial cells) (Riasu, 1997; Adams and Eichmann, 
2010). 
 
Anti-angiogenic agents and cancer therapy 
Knowledge of whether FAM198b contributes to angiogenesis is interesting with reference to 
basic science, but it also could aid in the discovery or refinement of agents that target the 
tumour vasculature. Blocking the development and advancement of established tumour 
vasculature has been explored as a method to complement, or even replace current anti-
cancer therapies. This option is particularly attractive as endothelial cells have intimate 
contact with the blood. Additionally anti-cancer therapies could be targeted to the tumour 
vasculature exclusively, as current anti-cancer therapeutics have a wide array of side effects. 
It has been known for some time that the endothelium differs in tumours from that of 
normal tissues. Tumour endothelium proliferates at a high rate and is a substantially 
contributes to angiogenesis. Whilst a small number of molecular differences have recently 
been characterised, many remain undefined (Neri and Bicknell, 2005). 
The VEGF signalling pathway was considered to be a promising target for anti-cancer 
therapeutics. This was largely due to the fundamental role VEGF plays in promoting 
angiogenesis and tumour growth. Currently two methods have been employed to target the 
VEGF signalling pathway. Bevacizumab (avastin) was the first angiogenesis inhibitor to be 
made available commercially for the treatment of breast, colorectal renal and lung cancers 
in combination with standard chemotherapy. Bevacizumab is a monoclonal antibody which 
binds to circulating VEGF-A. This tactic reduces angiogenesis by limiting the binding of VEGF-
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A to cell surface receptors (Chung et al., 2010; Kazazi-Hyseni et al., 2010). The second 
approach is based upon the specific targeting of the VEGF receptor complex. The tyrosine 
kinase inhibitors sorafenib (nexavar) and sunitinib (stutent) are capable of reducing 
angiogenesis. These molecules inhibit the phosphorylation of the VEGF receptors and 
therefore stop the activation of the angiogenesis cascade (Gupta and Zhang, 2005). 
The use of the anti-angiogenic drugs mentioned above has been effective with regard 
to improving the survival rates of cancer patients. However it is important to discover novel 
targets for anti-angiogenic drugs. This would allow for possibility of combination therapies 
being developed, which would allow for the efficiency of angiogenesis inhibition to be 
maximised. These developments are important because many cancer patients do not 
respond to the anti-angiogenic therapeutics or experience disease reoccurrence. The 
development of tumour resistance against anti-VEGF treatment could be caused by many 
factors. This resistance could be caused by the exploitation of alterative pro-angiogenic 
pathways or vastly upregulated levels of VEGF/VEGFR molecules (Chung et al., 2010; 
Nussenbaum and Herman, 2010). 
 
Models of angiogenesis 
The aim of this project is to determine whether FAM198b plays a role in angiogenesis 
tumourgenesis and wound repair. This will be carried out by utilising HUVECs as in vitro 
models following the knockdown of FAM198b with small interfering RNA (siRNA) molecules. 
siRNA has been recognised as a natural gene silencing mechanism in plants, vertebrates and 
invertebrates. In vitro siRNA mediated knockdown of gene expression has been achieved by 
transfecting mammalian cells with synthetic double stranded RNA molecules. The 
suppression of gene expression is mediated through highly regulated enzymatic reactions. 
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The RNA interference (RNAi) pathway requires the RNA-induced silencing complex (RISC) to 
bind to the anti-sense strand of the siRNA molecule. Once the siRNA has bound to the RISC 
and pathway has been activated, mRNA targets which are complementary to the siRNA 
molecule can be recognised and cleaved (Xia et al., 2002; Reynolds et al., 2004) 
In vitro models of angiogenesis are an indispensable prelimary tool for studying the 
molecular mechanisms involved in angiogenesis. The in vitro use of HUVECs allows for 
information to be gathered by imitating each of the three main phases involved in 
angiogenesis, migration, proliferation and tube formation.  To study these three phases, this 
preliminary study of FAM198b utilised the scratch wound healing, matrigel tube formation 
and proliferation assays. These assays have many limitations and are extremely simplistic 
when compared to the processed involved in angiogenesis. But these assays can provide 
invaluable information for the preliminary phases of investigating and validating potential 
therapeutic targets (Staton et al., 2006). 
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Materials and Methods 
Cell Culture 
Materials Source 
Human umbilical vein endothelial cells 
(HUVEC) 
Birmingham Women’s Hospital, Birmingham 
Media 199 Cancer research UK and Sigma, UK 
Bovine brain extracts 
Pel-Freez, USA. and prepared as described by 
Maciag et al. (1979) 
Fetal calf serum PAA, The Cell Culture Co., UK 
L-glutamine Sigma, UK 
Porcine skin gelatine Sigma, UK 
Trypsin-EDTA Sigma, UK 
FastRead Haemocytometer Immune Systems, UK 
Tryphan Blue Sigma, UK 
Leica DM IL inverted microscope Leica Microsystems, USA 
 
Method: 
Informed consent was obtained prior to obtaining human umbilical cords from Birmingham women’s 
health care NHS trust. Collagenase type 1a was used to isolate human umbilical vein endothelial cells 
(HUVECs) from umbilical cords using a standard protocol. Media 199 containing 10% (v/v) foetal calf 
serum (FCS), 90 µg/ml heparin, 4mM L-glutamine was supplemented with bovine brain extract and 
was used to culture the HUVECs to confluence. The cells were cultured in sterile plastic culture dishes 
coated with 0.1% (w/v) gelatine and maintained at 37°C in a humidified atmosphere with 5%CO2. 
The HUVECs were split and re-plated at a ratio of 1:3 once confluent. The HUVECs were 
detached from the culture dish by washing with 1x phosphate-buffered saline (PBS) and incubated in 
1xtrypsin-EDTA solution for 5 minutes in the conditions stated above. Once detached supplemented 
Media 199 was added to the cells before being centrifuged at 250 RCF for 5 minutes, the pellet was 
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resuspended in fresh supplemented Media 199 and the cells were plated for further cultivation. The 
HUVECs were only used for the following assays between passages 1 and 6. 
 
RNA analyses 
RNA extraction 
Materials Source 
QIAShredder Qiagen, UK 
RNeasy mini kit Qiagen, UK 
2-mercaptoethanol Sigma-Aldrich, UK 
70% ethanol (in RNase-free water) n/a 
 
Method: 
The HUVECs were lysed using the QIAShredder columns as according to the manufacturer’s 
instructions. RNA was purified from the lysate using the RNeasy mini kit (including the optional 
DNase step) according to the manufacturer’s instructions. 
 
Generation of cDNA 
Materials Source 
SuperScript III First-Strand Synthesis System Invitrogen, UK 
 
Method: 
SuperScript III First-Strand Synthesis System kit was used to generate total complementary cDNA 
from the isolated RNA according to the manufacturer’s instructions.  
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Real Time Quantitative Polymerase Chain Reaction 
Materials Source 
Sensimix™ Quantace, UK 
Universal Probe Library set, Human Roche Applied Science, UK 
PCR Primers Eurogenetec, UK 
Rotor-Gene RG-3000 qPCR machine Corbett Research Ltd, Australia 
Rotor-Gene 6 software Corbett Research Ltd, Australia 
 
Method: 
The Exiqon universal probe system was used to perform real time quantitative polymerase chain 
reaction (qPCR). A web based tool produced by Roche Applied Science was used to design the 
forward and reverse primers shown below. These primers amplify a region containing a sequence 
where a probe could bind and to amplify a product which crossed an exon boundary where possible 
(table 1). 
 A reaction mix totalling 25μL was used: 
 
 
 
 A Rotor-gene RG-3000 was used to conduct the qPCR using the 36 well rotors and the 
following program: 
 95°C for 10 minutes 
 95°C for 15 seconds 
 60°C for 45 seconds 
 12.5μL  Sensimix™ 
 1μL forward primer (10 μM) 
 1μL reverse primer  (10 μM) 
 
 0.25μL of the appropriate probe 
 0.25μL deionised water 
 10μL of cDNA 
 
40 Cycles 
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Table 1: PCR Primer sequences.  
The forward and reverse primer sequences are contained in this table. Additionally the specific probe 
number from the Universal Probe Library set for each amplicon has been included. 
 
 The expression levels of FAM198b were determined by using known dilutions of cDNA (1 in 
10, 1 in 100 and 1 in 1000) to generate standard curves using Rotor-Gene 6 software. The 
normalisation of expression to β-actin was used to accurately quantify gene expression and compare 
between different samples. 
Primers Sequence Probe 
Splice variant 1 (SV1) 
Forward - 5’ AAGCAGAGTTCATCCAAGCAG 3’ 
#64 
Reverse - 5’ TGCTGATAAGTTCCCAGGTG 3’ 
Splice variant 2 (SV2) 
Forward - 5’ ACAATTCTTCCTGGAGCCAAGC 3’ 
#33 
Reverse - 5’ AGAGGTGGAAGGAAAGGGTTG 3’ 
FAM198b Universal Splice 
Variant 
Forward - 5’ GAAAAAGCATGCAGTGGCATC 3’ 
#37 
Reverse - 5’ TACAGCATCAGCTTCCCTTGC 3’ 
Splice variant 1+3 (SV1+3) 
Forward - 5’ CTTCTAGGCCTTCTCTTTCCAG 3’ 
#31 
Reverse - 5’ CAAGGAGAAATGCGGCTTG 3’ 
β-actin 
Forward - 5’ GCACCCAGCACAATGAAGA 3’ 
#63 
Reverse - 5’ CGATCCACACGGAGTACTTG 3’ 
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siRNA Transfection and Knockdown of FAM198b 
Materials Source 
OptiMEM Invitrogen, UK 
Lipofectamine RNAi MAX Invitrogen, UK 
FAM198b specific duplexes Eurogentec, UK 
Negative control duplex  Eurogentec, UK 
Method: 
Two siRNA duplexes (table 2) were designed to target the coding region of FAM198b according to the 
criteria proposed by Reynolds et al. (2004). A third siRNA duplex was obtained from Eurogenetec 
(UK) which is not complementary to any known sequence. The Duplexes were diluted to working 
stocks of 20μM in RNase-free water and aliquoted to avoid repeated freeze-thaw cycling. 
 
Table 2: The siRNA duplex sequences for the FAM198b knockdown. 
The two duplexes were designed to specifically target the 3’ UTR of FAM198b. It is important to note that the 
3’ end of the duplexes were tagged with two thymine nucleotides (represented by the number 55). This 
modification creates an overhang at the 3’ end of the duplex and aids in the preferential destruction of the 
siRNA sense strand and binding of the anti-sense strand to the proteins in the RISC pathway. 
 
 HUVECs were seeded onto gelatine coated dishes the day before the cells were transfected 
with siRNA. The size of dish and number of cells varied depending on the assay being conducted 
(table 3). For transfection of HUVECs in single 10cm culture dish D1 and D2 or the negative duplex 
was diluted in 680μL of opti-MEM to give the appropriate final concentration. 10% (v/v) 
lipofectamine RNAi MAX was also diluted in opti-MEM to obtain a total volume of 120μL. Both 
SiRNA Duplex Sequence 
FAM198b Duplex 1 (D1) 5’-GAUAAAGUGUAUUGGGAAA55 
FAM198b Duplex  2 (D2) 5’-GAAUCGGGUUGUACUGAAA55 
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mixtures were incubated for 10 minutes at room temperature after gentle mixing. The two mixtures 
were combined, flicked and incubated for a further 10 minutes. After washing twice with PBS, 3.2mL 
of opti-MEM was added the cells. The 800 μL transfection mix was added to the cells to give a total 
volume of 4mL and mixed by tilting. The HUVECs were incubated at 37°C in a humidified atmosphere 
with 5% CO2 for 4 hours; the transfection mix was then replaced with fresh media 199 without 
antibiotics. The volumes required for the transfection mix was scaled down to accommodate 
transfection in a 6 well plate for the scratch wound healing assay. 
 
Table 3: The cell numbers and dish size required for each assay 
 
Angiogenesis Assays 
Cell Growth - Proliferation Assay 
Materials Source 
FastRead Haemocytometer Immune Systems, UK 
Tryphan Blue Sigma, UK 
Leica DM IL inverted microscope Leica Microsystems, USA 
 
Method: 
Three gelatine coated 6 well plates per condition were prepared for each condition. HUVECs were 
seeded onto the 6 well plates at a density of 9x104 cells four hours after the siRNA transfection. The 
number of cells per well were counted 1-3 days post seeding using a haemocytometer and a Leica 
DM IL light microscope. 
Assay Culture dish Number of cells siRNA Concentration 
Cell Growth 10cm plate 1x10^6 25nM D1 and 25nM D2 
or 
50nM Negative Duplex 
Wound healing 6-well dish 3x10^5 
Tube formation 10cm plate 1x10^6 
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Cell Migration - Scratch Wound Healing Assay 
Materials Source 
Mitomycin C Sigma, UK 
Leica DM IL inverted microscope Leica Microsystems, USA 
USB 2.0 2M Xli camera Leica Microsystems, USA 
Image J Software National Institutes of Health 
 
Method: 
48 hours after the HUVECs were transfected with the siRNA (as described above) vertical scratches 
were made with sterile 200µL pipette tips. Cell debris from the scratch process was washed of with 
PBS before adding fresh media containing 2.5µg/mL mitomycin C and incubating at 37°C in a 
humidified atmosphere with 5%CO2 for 8 hours. The amount of cell migration was observed by taking 
pictures at 0, 4 and 8 hours from the same location using a USB 2M Xli camera and a Leica DM IL 
microscope. The pictures were analysed using Image J software to quantify the wound healing by 
measuring the area of wound remaining open. The percentage of the scratch wound remaining open 
was calculated by dividing the area of the wounds at 4 or 8 hours by the area measured at 0 hours, 
wounds were considered to be 100% open at the 0 hour time point. The degree of wound closure 
could then be compared between the knockdown of FAM198b and the negative duplex at each time 
point. 
 
Tube formation - Matrigel ™ Tube Formation Assay 
Materials Source 
BD Matrigel™, basement membrane matrix VWR, Canada 
Leica DM IL inverted microscope Leica Microsystems, USA 
USB 2.0 2M Xli camera Leica Microsystems, USA 
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Method: 
HUVECs were used 24 hours after transfection with siRNA for the tube formation assay. Matrigel™ 
was thawed overnight was thawed overnight at 4°C and kept on ice before being added to 12 well 
plates. The 12 well plates were washed with PBS before adding 70µL of Matrigel™, which was 
allowed to solidify at 37°C for 30 minutes. The transfected cells were seeded on top of the Matrigel™ 
at a density of 1.4x105 in 1mL of complete Media 199. The HUVECs were incubated for 10 hours at 
37°C in a humidified atmosphere with 5%CO2 and tube formation was observed by taking pictures of 
5 random fields of vision at 10 hours. The degree of tube formation for each condition was quantified 
by counting the number of nodes with two, three or four or more branches per field of vision. 
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Results 
FAM198b Expression 
Real time quantitative PCR (qPCR) was conducted to assess whether FAM198b was truly 
expressed in HUVECs (Figure 5). It was determined that splice variant 2 was definitely 
expressed. However the first splice variant could not be amplified, this could be because the 
splice variant was not expressed in HUVECs or because of primer inefficiency. It is important 
to note that the 5’ UTR shared by the first and third variants was amplified and therefore at 
least one of those splice variants exists. 
  
Figure 5: qPCR expression data to confirm the expression of FAM198b 
The expression levels of the splice variants above were determined by deducting the cycle threshold of the 
house keeping gene, β-actin, from the cycle threshold of the FAM198b signal to obtain the Delta cycle 
threshold values (DCT). 
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Confirmation of knockdown 
In the absence of specific antibodies for FAM198b qPCR was the only method by which the 
expression of FAM198b could be monitored post knockdown (Figure 6). The qPCR results 
demonstrate that duplex 1 and 2 successfully knocked down FAM198b by roughly 90%. 
 
Figure 6: qPCR data to confirm the efficiency of the siRNA knockdown 
The FAM198b expression levels for both the double knock down and negative control were compared to an 
internal β-actin control, which allowed for the calculation of 2
-DDCT
.  
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Angiogenesis Assays  
Cell Growth - Proliferation Assay 
The proliferation assay shows that for the first two days after transfection there is not a 
difference in cell growth between the cells that have been transfected with duplexes to 
knockdown FAM198b and the negative control duplex. But by the third day there was a 
difference between the cells that had been knocked down and the negative control, fewer 
HUVECs were counted for the group which had been knocked down (figure 7). However 
whilst the means differed by over 150,000 cells and the error bars did not overlap, the 
difference was determined to not be statistically significant when the p value was calculated 
using the ‘Kruskal–Wallis one-way analysis of variance’. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: The effect a FAM198b knockdown has on cell growth 
Cell counting using a haemocytometer was used to quantify the difference of cell growth between the cells 
transfected with D1 and 2 and the negative duplex. The error bars represent the standard error of the mean 
number of cells at each time point per condition. The P value was calculated using the Kruskal–Wallis one-way 
analysis of variance statistical test, which compared the variance between the raw data sets for each condition.
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Cell Migration - Scratch Wound Healing Assay 
The scratch wound healing assay shows that there was a small increase in migration when 
the HUVECs had been knocked down with siRNA targeting FAM198b (figure 8). The 
increased speed of  was quantified to be just over 10% faster when FAM198b was knocked 
down, furthermore this difference was determined to be statistically significant at both 4 
and 8 hours. 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: The effect a FAM198b knockdown has on scratch wound healing 
A) The pictures of the scratch wounds were taken at the same location for each time point using a USB 2M Xli 
camera and Leica DM IL microscope. 
B) Six independent scratch wounds per condition were analysed using Image J software, which allowed for the 
quantification of scratch wound healing. The scratch wounds at 0 hours were considered to be 100% open, 
whereas the percentage wound healing at 4 and 8 hours was determined by comparing the area at these time 
points to the scratch at 0 hours. The error bars represent the standard error of the mean amount of scratch 
wound remaining open. The P value was calculated using the Kruskal–Wallis one-way analysis of variance 
statistical test.
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Tube formation - Matrigel™ Tube Formation Assay 
The two dimensional Matrigel™ tube formation assay demonstrated that when FAM198b 
has been knocked down there is an effect on tube formation (figure 9). The number of nodes 
forming two or three branches is statistically lower when FAM198b has been knocked down.  
However the number of nodes with four or more branches was similar for both conditions, 
the nodes formed by HUVECs that had been knocked down appeared to be larger.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: The effect a FAM198b knockdown has on tube formation 
A) The pictures obtained from the USB 2M Xli camera and Leica DM IL microscope demonstrate that the level 
of tube formation by HUVECs with the FAM198b knockdown compared to cells transfected with the negative 
duplex.  
B) The degree of tube formation was quantified by counting the number of nodes with 2, 3 or 4 or more 
branches. The error bars represent the standard error of the mean number of nodes per field of vision. The P 
values were calculated using the Kruskal–Wallis one-way analysis of variance statistical test.
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Discussion 
Real time quantitative PCR has been a valuable tool in this project. It was initially useful for 
confirming that HUVECs expressed the second splice variant and the alternate exon in the 5’ 
prime region of the first and third splice variant. As there were no specific antibodies 
available for the detection of FAM198b, qPCR provided a simple way to detect and quantify 
the expression of FAM198b following knockdown with siRNA. A double knockdown of 
FAM198 with duplex 1 and 2 was used to transfect the HUVECs. This strategy provided a 90% 
knockdown of FAM198b compared to β actin. The double knockdown was employed 
because a greater degree of knockdown could be obtained. Additionally by employing a 
double knockdown the required concentration of each siRNA duplex could be halved. Not 
only could the high concentrations of siRNA provide a prolonged knockdown, but also there 
was less chance of off-target silencing because a lower concentration of each siRNA 
molecule was used. 
 The use of qPCR for confirming the knockdown of FAM198b relies upon the 
assumption that protein encoded by FAM198b has a short life-span. qPCR can be used to 
determine the effectiveness of the duplexes at the mRNA level. But it is not possible to know 
whether this relates to an equivalent reduction of FAM198b protein. However qPCR was the 
only viable option available to confirm the knockdown due to the short duration of the 
project. Additionally this limitation is not significant if an effect is observed after the 
knockdown, because for this difference to occur there must have been a significant protein 
deficiency.  
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Angiogenesis assays 
The greatest difference in cell growth was observed on the third day following the FAM198b 
knock down. This result could indicate that without the expression of FAM198b HUVECs are 
not able to proliferate as efficiently. But the effect of the FAM198b knockdown was 
determined to not be statistically significant when comparing the raw data sets using the 
Kruskal–Wallis one-way analysis of variance. There is a large difference between the means 
of the data and the error bars do not overlap, which indicates that FAM198b could have a 
real effect on cell growth. More replicates over a greater time period would be required to 
explore this possibility. Should a significant effect be seen, additional assays would have to 
be carried out to determine whether FAM198b has a direct effect on proliferation and which 
stage of the cell cycle FAM198b effects. But also the possibility that the absence of FAM198b 
in HUVECs induces apoptosis or whether duplexes 1 and 2 induce tumour necrosis factor-α 
(TNFα) induced apoptosis. 
 The knockdown of FAM198b significantly increases the rate of scratch wound healing. 
This effect was solely due to the migration of HUVECs, as mitocycin C was used to ensure 
that the HUVECs could not proliferate. An increase in the rate of migration indicates that 
FAM198b could be either an adhesion factor or involved in the signalling, stability, 
production or trafficking of adhesion factors (Sanabria et al., 2011). 
 The scratch assay was conducted 48 hours following knockdown. It is possible that a 
greater difference in migration could have been observed if the scratch wound assay was 
conducted at a later time point. A greater length of time between the knockdown and the 
assay could have resulted in a further reduction of residual FAM198b, providing the 
knockdown remained effective.  
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 The effect of FAM198b on migration could also be explored using Dunn and Boyden 
chambers. These assays could be more useful than the scratch assay if FAM198b had a 
function relating to adhesion factors of cytoskeletal dynamics. Dunn and Boyden chambers 
assess the ability of cells react to chemokinetic and chemotactic factors in addition to their 
ability to migrate and squeeze through pores in filters. The ability to move through the filters 
is heavy influenced by the activity of adhesion molecules and cytoskeletal remodelling 
(Staton, 2006). It would also be interesting to carryout further scratch wound assays to 
determine whether HUVECs over expressing FAM198b migrated at a slower rate. 
The matrigel™ tube formation assay demonstrated that FAM198b depleted cells 
were able to align themselves into primitive tube-like structures. Connolly et al. (2002) has 
described the changes that contact with Matrigel™ induces in HUVECs. These changes 
include the cellular protrusions and microtubule dynamics required to align HUVECs into 
short tube-like structures. FAM198b depleted HUVECs appear to be capable of making these 
changes. However quantitative analysis revealed that the knockdown of FAM198b appeared 
to cause an increase in node size. Additionally there was a statistically significant decrease in 
the number of nodes being formed with fewer than four branches compared to the control 
HUVECs. This indicates a reduced ability for FAM198b deficient cells to effectively 
differentiate, migrate and form the complex tubule networks. 
It is important to note that the results from this assay coincide with the microarray 
results published by Sun et al. (2005), which were highlighted in the introduction. FAM198b 
appeared to be upregulated in endothelial cells, indicating a possible involvement during the 
later stages of tubule formation.  
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 The results from these in vitro assays indicate that FAM198b could play a significant 
role in angiogenesis. But it is important to note that this study does have some limitations. 
Firstly the HUVECs for these assays were derived from only one umbilical cord and therefore 
only one patient. It is possible that the knockdown of FAM198b would not have had 
significant results if the cells were derived from another patient, due to the genetic 
variability between individuals. Additionally, the use of HUVECs has some associated 
limitations, despite being a widely used model for in vitro angiogenesis assays. The results 
from the FAM198b knockdown observed in HUVECs might not relate accurately the role of 
FAM198b in an adult, as HUVECs are derived from foetal material. 
 Further research into the role of FAM198b could be justified based on the results 
presented in this study. But this research would have to demonstrate that the effects 
reported in this paper occurred in HUVECs from multiple patients. Additionally more in vitro 
assays could be employed, such as those discussed earlier. In the longer term some in vivo 
assays could be employed to verify the effect of FAM198b in a more complex environment. 
For example zebrafish could be used to analyse the knockdown and over expression of 
FAM198b. This model had many advantages because zebrafish embryos are transparent and 
embryogenesis occurs rapidly outside the mother’s body, which allows for easy observation 
of vascular development, which can be carried out in real-time (Staton, 2006).  
FAM198b is predicted to be a golgi membrane protein, which presents challenges for 
the development of therapies. It would not be possible to use relatively simple therapies 
which would target proteins on the cell membrane, such as monoclonal antibodies. 
Currently no anti-angiogenic specific therapies are in clinical use which target proteins 
contained within endothelial cells. But it could be possible to target FAM198b using small 
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organic molecules. This would require the large scale screening of compounds using nuclear 
magnetic resonance imaging to identify compounds with sufficient structure-activity 
relationships to FAM198b (Neri and Bicknell, 2005). 
 A significant disadvantage of FAM198b as a therapeutic target is that the microarray 
data discussed earlier in this paper suggests that FAM198b could be expressed in many 
tissues. Ideally it would be best for a prospective target to only be present in tumour 
vasculature. But as the object of these therapies is to inhibit angiogenesis FAM198b could 
still be an appropriate therapeutic target. Further experimental work would be required to 
determine that FAM198b is not essential to the viability of non-cancerous tissues. If 
FAM198b is not essential to the viability of those tissues, it could be an appropriate target 
for use in a combination therapy along side bevacizumab, sorafenib or sunitinib. 
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Conclusion 
Many genes are involved with the regulation of angiogenesis. The in vitro assays detailed in 
this paper indicate that FAM198b plays a role in allowing HUVECs to migration and form 
tubules. These results support the unverified microarray data published by Sun et al. (2005), 
which indicated that FAM198b was upregulated during endothelial sprouting, branching, and 
capillary network formation. Angiogenesis is a natural process involved in wound healing, 
which can be hijacked and contribute to tumourgenesis. If FAM198b was determined to 
significantly affect angiogenesis and endothelial cell viability in vivo, FAM198b could be 
utilised as a novel target for ant-angiogenic therapeutics. Anti-angiogenic therapies could be 
a significant tool to selectively kill or limit the potential for tumour cells to rapidly 
proliferate. This option is preferential to conventional cancer therapies because 
chemotherapy is non-specific and can cause significant toxicity to proliferating non-tumour 
cells. 
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Appendix 
Cloning and FAM198b GFP fusion 
FAM198b is predicted to be a golgi membrane protein, to confirm this aFAM198b-GFP fusion 
was to be produced. However due to the short time frame for the project this work was not 
completed. Both an N terminal and C terminal GFP tag were to be generated as the structure 
of FAM198b was not known. Using this strategy it was hoped that at least one of the 
constructs would yield a functional protein. 
pEGFP N1 
 
 
 
 
 
 
CMV 1  GFP FAM198b  
 34 
Forward Primer 
ECORI 
5’ TAG TAG GAA TTC GCC ACC atg cgg cag aga aat gac ctg t 3’ 
34 bases  
Reverse Primer 
SALI 
5’ CTA CTA GT CGA CGT ttc att cat agg taa gat tac t 3’ 
34 bases -  
pEGFP C1 
 
 
 
 
CMV 1  GFP FAM198b  
 35 
 
Forward Primer 
ECORI 
5’ TAG TAG G AAT TCT atg cgg cag aga aat gac ctg t 3’ 
Reverse Primer 
SALI 
5’ CTA CTA GTC GAC tca ttc att cat agg taa gat t 3’ 
 
There were some concerns that the C1 construct would not work because a bioinformatics program 
predicted FAM198b to have a cleavage site near the start of the FAM198b protein. 
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Introduction 
The craniofacial tissues have been associated with a wide range of clinical manifestations. 
These can include acquired damage to the skull and facial tissues through a wide array of 
traumatic injuries, tumour invasion and congenital disease. Additionally malformation of the 
craniofacial tissues can be associated with many congenital abnormalities. Abnormalities 
and damage to the craniofacial tissues can be associated with many symptoms. The 
craniofacial tissues can be affected cosmetically and even functionally. For example 
congenital and acquired craniofacial deformities can be associated with an insufficiency of 
sight, sound perception, speech, breathing, mastication (chewing) and swallowing (Yoneno 
et al., 2005) 
 Corrective surgery has been attempted using materials from the iliac, often the hip 
bone, to create grafts. However this strategy requires the removal of a significant amount of 
tissue and sufficient donor material is not always possible. Additionally this degree of 
surgical intervention can result in an increased level of morbidity and mortality (Yoneno et 
al., 2005). To a degree these problems can be overcome through the practise of 
allotransplantation (the use of tissues from other individuals of the same species). However 
even this is associated with significant clinical limitations, largely due to the problems 
associated with immunogenicity and donor availability (Seidi et al., 2011). 
 Tissue engineering has the potential to overcome the limitations of the conventional 
therapeutic techniques. Not only could tissue engineering provide donor material with 
limited problems associated with immunogenicity. But also the grafts could be capable of 
integrating with host tissues more efficiently than a conventional graft (Yoneno et al., 2005; 
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Seidi et al., 2011). This paper will focus on the use of bone marrow stem cells (BMSCs) and 
the materials and techniques associated with tissue engineering. However the use of tissue 
engineering to overcome specific craniofacial abnormalities is beyond the scope of this 
investigation. 
 Tissue engineering is a branch of science which aims to utilise advances in the fields 
of molecular biology, cell biology, material science and bioengineering. The broad aim of 
tissue engineering is to repair or regenerate the function of tissues in areas that have been 
damaged. This can be achieved by either the in vitro generation of functional tissues by the 
time of implantation into a patient. Alternatively materials can be implanted into a patient, 
which allow for the generation of functional tissues in vivo. Tissue engineers have typically 
attempted to generate grafts containing a single tissue, for example cartilage, bone or skin. 
However interface tissue engineering is emerging as a field which aims to create functional 
tissues containing different tissues. This approach could be particularly effective for the 
reconstruction of areas requiring both hard and soft tissues (Seidi et al., 2011). 
Tissue engineering can utilise small biopsies obtained from the patient as opposed to 
conventional surgical techniques. Cells can be isolated from the biopsies and cultured to 
obtain large numbers of cells. This approach could overcome the problems associated with 
the availability of donor material and immunocompatibility (George et al., 2006; Seidi et al., 
2011). The isolation of stem cells which are capable of differentiating into many lineages 
could be very useful for the creation of these tissues. Bone marrow derived stem cells could 
be isolated from the patient, cultured on three-dimensional (3-D) bio-degradable scaffolds.  
The scaffolding could be created through the use of synthetic or organic materials. Tissue 
engineers aim to direct the formation of tissues and structures resembling those found in a 
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living person. This would be facilitated by utilising chemical and biochemical molecules or 
the properties of the scaffold itself to stimulate the growth of stem cells and direct their fate 
(Yoneno et al., 2005; George et al., 2006; Seidi et al., 2011). 
With regard to stem cell therapy the use of the techniques associated with tissue 
engineering could be particularly effective. Stem cells have been shown to yield poor survival 
when injected directly into tissues. Largely due to the lack extracellular support and 
presence of necrotic tissue associated with areas of scarring and injury (Burns et al., 2009; 
Yamashita et al., 2009).  The definition of a true stem cell is often debated in the literature. 
But stem cells are generally considered to be undifferentiated cells which are capable of 
maintaining a population of stem cells and spontaneously differentiating into other cell 
types (figure 1). Stem cells should also be capable of repopulating tissues regardless of 
whether significant damage has inflicted to the tissue or not (Stojanoski et al., 2009; 
Verfaille, 2009). 
Many types of stem cells can be utilised by tissue engineers to produce tissues for 
craniofacial regeneration, but BMSCs (a variety of mesenchymal stem cell) could be 
especially useful. Mesenchymal stem cells are multipotent stem cells (stem cells which are 
capable of differentiating into a limited number of cell types), which are typically isolated 
from bone marrow and therefore should not raise ethical issues. However mesenchymal 
stem cells but can also be obtained from other sources such as placenta and adipose tissue. 
Mesenchymal stem cells are derived from the mesoderm (figure 2) and are particularly 
useful for craniofacial regeneration because they have been shown to spontaneously 
differentiate into cells contained within bone, cartilage and adipose tissues. All of which can 
be naturally involved in make up of a diverse range of craniofacial structures. Furthermore 
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bone marrow stem cells have been shown to differentiate into tissues outside of their own 
lineage, such as neurons, which are typically derived from the ectoderm. Mesenchymal stem 
cells are also favoured by tissue engineers because of their weak immunogenicity and 
immunomodulatory properties. Their immunomodulatory properties in particular could be 
very useful as inflammation could cause damage to the grafts (Yoneno et al., 2005; George 
et al., 2006; Schenke-Layland et al., 2007; Hicks and Jolkkonen, 2009). 
 
 
Figure 1: The division strategies employed by stem cells 
A: Asymmetric Division: Two non-identical daughter cells are produced in this process. One cell differentiates 
into another cell type whilst the other would remain identical to the progenitor cell. 
B. Symmetric Division: - Two daughter cells which both have identical when compared to the progenitor.  
(Original diagram compiled using information from Stojanoski et al., 2009 and Verfaille, 2009) 
 
A B 
Progenitor cells 
undifferentiated 
daughter cells 
undifferentiated 
daughter cell 
differentiated 
daughter cell 
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Figure 2: The formation of the germ layers and mesenchymal stem cells 
A blastocyst is a hollow sphere of cells (blastoderm), which contains a layer of cells known as the inner cell 
mass. The blastoderm has the capacity to differentiate into all the cell types contained within the placenta. 
Whereas the inner cell mass can differentiate into over 200 cell types and forms the foetus. The inner cell mass 
will initially form three germ layers, the endoderm, mesoderm and ectoderm. (Original diagram compiled using 
information from Hwang et al., 2009). 
 
BMSCs can be differentiated into osteoblasts, chondrocytes and adipocytes within 
various 3-D cell scaffolds. The conventional method of gaining a specific tissue type has been 
to expose the BMSCs to molecules that stimulate differentiation within the collagen scaffold. 
These methods include exposing BMSCs to transforming growth factor-β1 to obtain 
chondrocytes, dexamethasone to obtain osteoblasts, insulin and indomethacin to obtain 
adipocytes, and 5-azacytidine to obtain myoblasts (Yoneno et al., 2005). 
Morula Zygote 
Blastocyst 
Placenta 
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Collagen scaffolds have great potential for these purposes as they form a honeycomb 
structure to which cells can attach, proliferate and differentiate within (George et al., 2006). 
Collagen has many advantages when compared to other scaffolding materials. Collagen is 
the most abundant protein in mammals and is a major component bone, cartilage and the 
extracellular matrix. Collagen has the relevant mechanical properties needed for a 3-D 
scaffold, with regard to plasticity and physiological stiffness. Furthermore collagen 
participates in the cell growth and differentiation in vivo (Yoneno et al., 2005). 
There is increasing evidence in the scientific literature that cells are capable of 
responding to environmental signals of a physical nature. Substrate elasticity has been 
shown to influence a wide array of cellular behaviour. Substrate elasticity can affect cell 
morphology, survival potential, growth, migration and differentiation. Soft substrates induce 
cells to have lower cytoskeletal tension causing cells to appear round and small. It has also 
been shown that BMSCs cultured on thick or soft collagen gels can become quiescent. 
Whereas stiff substrates induce cells to form a rigid wide-spread morphology and express 
contractile stress fibres (Leong et al., 2010).  A notable example of the ability of 
mesenchymal stem cells to react to an extracellular matrix constructed from collagen type 1 
was presented by Engler et al. (2006). Mesenchymal stem cells demonstrated the potential 
to differentiated into different lineages such as neurons, myoblasts and osteoblasts when 
exposed to different substrate stiffness. 
Schenke-Layland and colleagues (2007) described another particularly interesting 
case of extracellular matrix modulation and its effects on mouse embryonic stem cells 
(mESCs). It is widely believed that mESCs, derived from the inner cell mass have irreversibly 
committed to an epiblast lineage and that genetic manipulation would be required to trigger 
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differentiation into the placental lineages derived from blastoderm. However upon exposure 
to collagen IV, which is a component of the basement membrane, mESCs are capable of 
differentiating into cells associated with the placental lineage. This is not only interesting 
because it demonstrates the ability of stem cells to react to the extracellular matrix, but also 
because it challenges the definition of a pluripotent stem cell. 
There are three main methods of containing cells within a hydrogel scaffold, 
including collagen scaffolds. The first method is matrix adhesion, where the cells bind within 
hydrogel foams. The hydrogel foams rely on the creation of a macroporous network, which 
can be created using the gas bubbles from sodium bicarbonate. When using matrix 
adhesion, the cells are usually allowed to attach onto the surface of the collagen gel and 
migrate into the gel (Jen et al., 1996). 
The second method is known as matrix entrapment (or macroencapsulation), where 
cells are physically constrained within the hydrogel network. Collagen is a particularly 
suitable material for matrix entrapment because collagen naturally produces a crosslinked 
porous network, which allows for the transport of nutrients and removal of waste. Despite 
the restriction of migration this method has a couple of advantages, namely that in vivo the 
entrapped cells are protected from mechanical and immunological damage (Jen et al., 1996). 
The third method is known as microencapsulation, which shares many properties of 
matrix entrapment. However microencapsulation relies upon the coating of single cells or 
small clusters of cells within a thin layer of semi-permeable scaffolding. Microencapsulation 
is generally used as a method of transplanting cells into a patient who requires the supply of 
hormones or other bioactive secreted products. (Jen et al., 1996). However matrix adhesion 
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and matrix entrapment are more appropriate techniques for the regeneration of craniofacial 
tissues.  
Currently the ability of stem cells to react to the extra-cellular matrix has only been 
explored in two-dimensional (2-D) cell culture systems. This paper describes explores the 
preliminary stages of setting up a project to investigate the reaction of BMSCs to 
extracellular matrix modulation in a 3-D collagen culture system. This would involve defining 
the extracellular matrix conditions, cell densities and time required for any reactions to take 
place. Hypothetically BMSCs could react differently when exposed to 3-D gels of different 
thicknesses and stiffness (differential collagen concentrations). If in the longer term collagen 
density and gel thickness were to be found to impact upon potential for BMSC to 
differentiate into different lineages interface tissue grafts could potentially be produced. 
These grafts could be employed for craniofacial regeneration by utilising scaffolds 
constructed with collagen gels of different properties. It could even be possible to utilise 
both matrix entrapment and matrix adhesion, if these methods cause BMSCs to 
demonstrate different phenotypes. 
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Materials and Methods 
Extraction of Collagen from rat tails 
Materials Source 
Tails from 250-280g Wistar Hann rats Aston University Animal House, Birmingham 
Sterile Distilled Water n/a 
1% Glacial acetic acid Sigma-Aldrich, UK 
 
Methods 
The tails were removed from 250-280g Wistar Hann rats. It is important to note that the tails were 
removed from rats that were sacrificed for other purposes, as it was not thought to be morally 
responsible to sacrifice rates only for the tails. The tails were skinned, tendons removed and placed 
in sterile water. To gain a near-pure collagen solution it is important to ensure that the tendons were 
free from other tissues. After washing three times in sterile water the tendons were removed from 
the water and weighed. For every 1g of tendon, 100ml of sterile water and glacial acetic acid was 
added to the water to give a final concentration of 1%. The solution was stored in a cold room at 4°C 
for 48 hours on a magnetic stirrer. Following the incubation the mixture was centrifuged at 10000 
rpm for 90 minutes at 4°C, pellet discarded and the supernatant was stored at 4°C. 
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The Purity of Isolated Collagen 
Materials Source 
Collagen solution from rat tails n/a 
Deionized Water n/a 
Tris-Acetate Poly Acrylamide Gel (Invitrogen, ) 
NuPage LDS Sample Buffer (4X) (Invitrogen, ) 
Tris-Glycine Native Sample Buffer (2X) (Invitrogen, ) 
XCell SureLock™ Mini-Cell Electrophoresis System (Invitrogen, ) 
Himark unstained molecular weight marker (Invitrogen, ) 
Glacial Acetic Acid Sigma-Aldrich, UK 
Methanol Sigma-Aldrich, UK 
Coomassie blue stain R-250 Thermo Scientific 
 
Methods 
Poly Acrylamide Gel Electrophoresis (PAGE) 
The PAGE was conducted as described in the manufacturer’s instructions. It is important to note that 
a native PAGE was conducted, as opposed to a denaturing PAGE. This allows for the collagen 
monomers and dimers to be visualised. The wells were loaded with 20µL of the Himark unstained 
molecular weight marker, 10µL test mix, which included 1 µL of Collagen Stock Solution, 4 µL sterile 
water and 5µL of the native sample buffer. An additional test mix was made containing the collagen 
stock solution, which had been centrifuged for an additional 90 minutes at 14000rpm. This was 
conducted to determine whether improvements could be made for the solution purity. 
 
Coomassie Blue Staining 
Once the PAGE had been conducted the gel was removed from the gel cartridge and prefixed 
overnight in an appropriate volume of 50% methanol, 10% glacial acetic acid and 40% deionized 
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water. Following this incubation 0.25% Coomassie blue R-250 was added for 4 hours to stain the gel. 
The gel was then destained for 12 hours in 1L 5% methanol, 7.5% glacial acetic acid and 87.5% 
deionized water. At which point the gel could be imaged or stored in 7% glacial acetic acid. 
 
Quantification of Collagen Concentration 
Materials Source 
Collagen solution from rat tails n/a 
L-4-hydroxyproline Sigma-Aldrich, UK 
Chloramine-T Sigma-Aldrich, UK 
P-dimethylaminobenzaldehyde Sigma-Aldrich, UK 
Sodium acetate citric acid Sigma-Aldrich, UK 
Sodium Hydroxide Sigma-Aldrich, UK 
Glacial Acetic Acid Sigma-Aldrich, UK 
n-Propanol Sigma-Aldrich, UK 
Perchloric Acid Sigma-Aldrich, UK 
Sodium Chloride Sigma-Aldrich, UK 
 
Methods 
Hydroxyproline assay 
The hydroxyproline assay was conducted as described by Reddy and Enwemeka (1996). The collagen 
stock solution was compared to a standard curve of hydroxyproline. The standard curve was made 
up of 0.5, 1, 1.5, 2, 2.5, 3µg hydroxyproline in a total volume of 50µL. 
 
Collagen Precipitation 
The collagen was precipitated out from the solution to provide a simple method of validation for the 
hydroxyproline assay results. Collagen can be precipitated out from a solution by adding 200 µL 
of30% NaCl in 0.5N acetic acid for every 1mL collagen solution in a pre-weighed tube. This solution is 
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left over night before being centrifuged at 10000 rpm for 90 minutes at 4°C to pellet the collagen. 
Once the supernatant has been poured off the pellet can be left in the open tube for an hour to allow 
the remaining solution to evaporate and weighed.  
 
Culture of Bone Marrow Stem Cells 
Materials Source 
Femurs from 250-280g Wistar Hann rats Aston University Animal House, Birmingham 
Dulbecco's Modified Eagle's Medium(DMEM) Sigma, UK 
Fetal calf serum PAA, The Cell Culture Co., UK 
L-glutamine Sigma, UK 
Penicillin and Streptomycin  Sigma, UK 
Trypsin-EDTA Sigma, UK 
FastRead Haemocytometer Immune Systems, UK 
Tryphan Blue Sigma, UK 
Leica DM IL inverted microscope Leica Microsystems, USA 
 
Methods 
The isolation and growth of bone marrow cells was conducted using 1xDMEM supplemented with 
20% FCS, 1% Pen/strep, 10% FCS and 4mM L-glutamine. The femurs were removed from the male 
Wistar Hann rats and soft tissue cleaned off before storing in sterile media. The condyle ends were 
removed and bone marrow flushed out in 5ml of media using a 23 gauge needle and 10 ml syringe 
and collected in a 15ml falcon tube. The bone marrow cells were then and transferred to a 75 ml 
tissue culture flask and made up to 10ml of sterile media and cultured at 37°C with 5% CO2 in a 
humidified incubator. The media was replaced every two days until the cells reached confluence. At 
which point the cells were detached from the culture dish by washing with 1x phosphate-buffered 
saline (PBS) and incubated in 1xtrypsin-EDTA solution for 5 minutes in the conditions stated above. 
Once detached supplemented DMEM was added to the cells before being centrifuged at 250 RCF for 
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5 minutes, the pellet was resuspended in fresh supplemented DMEM and the cells were plated for 
further cultivation. The bone marrow stem cells were used by passage 2. 
 
Preparation of Collagen Gel 
Materials Source 
Collagen solution from rat tails n/a 
Dulbecco's Modified Eagle's Medium(DMEM) Sigma, UK 
Sodium bicarbonate Sigma-Aldrich, UK 
Sodium Hydroxide Sigma-Aldrich, UK 
Flat bottomed 24 well plates Appleton Woods 
Passage 2 Bone Marrow Stem Cells n/a 
FastRead Haemocytometer Immune Systems, UK 
Tryphan Blue Sigma, UK 
Leica DM IL inverted microscope Leica Microsystems, USA 
 
Methods 
The collagen gels were made up in volumes suitable for a 24 well plate to test the reaction of bone 
marrow stem cells to different collagen concentrations and thicknesses. The specific concentrations 
of each reagent are detailed in table 1. The collagen solution was measured out into the 24 well 
plates, to which 1N Sodium hydroxide was added. 5xDMEM buffered with 1x Sodium bicarbonate 
containing 5x105 cells (if required) was then added. The gel mix can be transferred, after being mixed 
well, to a humidified incubator at 37°C with 5% CO2 for one hour. Examine the gel mix to ensure that 
the gel has formed formation; once the gels have solidified the gels can be immersed in complete 
DMEM. The media was changed every two days. 
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Condition Materials Quantity Blank Control 
Thick Gel 
(1.3% Gel) 
Well 1 2 3 4 5 6 
Collagen 400µL 400µL 0 
5xDMEM 560µL 560µL 0 
Cell/ml 5x10^5 0 5x10^5 
NaOH 40µL 40µL 0 
Total 1mL 1mL 0 
Thin Gel 
(1.3% Gel) 
Well 7 8 9 10 11 12 
Collagen 100µL 100µL 0 
5xDMEM 140µL 140µL 0 
Cell/ml 5x10^5 0 5x10^5 
NaOH 10µL 10µL 0 
Total 250µL 250µL 0 
Condition Materials Quantity Blank Control 
Low Collagen 
Concentration 
(1% Gel) 
Well 13 14 15 16 17 18 
Collagen 150µL 150µL 0 
1% Acetic Acid 50µL 150µL 0 
5xDMEM 180µL 180µL 0 
Cell/ml 5x10^5 0 5x10^5 
NaOH 20µL 20µL 0 
Total 500µL 500µL 0 
High Collagen 
Concentration 
(2% Gel) 
Well 19 20 21 22 23 24 
Collagen 300µL 300µL 0 
1% Acetic Acid 0 0 0 
5xDMEM 180µL 180µL 0 
Cell/ml 5x10^5 0 5x10^5 
NaOH 20µL 20µL 0 
Total 500µL 500µL 0 
Table 1: Constituents of the collagen gels prepared for the live dead assay 
 
Cell viability within Collagen Gels 
Materials Source 
Collagen Gels n/a 
LIVE/DEAD® Cell Viability Assay Invitrogen, UK 
Nikon TE2000-E Fluorescent Microscope Nikon, UK 
Nikon D70 Camera Nikon, UK 
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Methods 
Live Dead Assay 
The DMEM was carefully aspirated from the surface of the collagen gels before immersing the gels in 
0.2µg/ml Calcein acetoxymethylester (Calcein-AM) and 2.5µg/ml Propidium Iodide (PI) according to 
the manufacturer’s instructions. Calcein-AM stain lives cells green and PI stains dead cells red, this 
can be imaged using a Nikon TE2000-E Fluorescent Microscope. 
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Results 
The Purity of Isolated Collagen 
Coomassie blue is a non-specific protein stain, which should stain all proteins present at a 
concentration of at least 0.5µg/cm2. Figure 3 demonstrates that the methodology to isolate 
a relatively pure collagen solution was successful and capable of achieving results similar to 
those published by Horiguchi et al. (2008). 
 
Figure 3: PAGE and Coomassie Blue staining to determine the purity of isolated collagen 
Well Layout:  1 - Himark unstained molecular weight marker 
2 - Collagen Stock Solution 
3 - Collagen Stock Solution after additional centrifugation 
Four bands can be identified clearly for each well containing a test sample, representing collagen type-1 alpha-
1 (Col1a1) monomers (140 kDa), Col1a1 homodimers (280 kDa), collagen type-1 alpha-2 (Col1a2) monomers 
(125 kDa) and Col1a1/Col1a2 heterodimers (219 kDa). Additional centrifugation does not seem to enhance the 
purity of the collagen solution. 
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Quantification of Collagen Concentration 
Hypoxyproline is a post translational product of proline hydroxylation catalysed by an 
enzyme prolyhydroxylase. This imino acid is thought to be exclusive to collagen. The 
concentration of Hydroxyproline within a sample can be used to estimate collagen 
concentration through the construction of a standard curve (figure 4). 
Hydroxyproline Assay
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Figure 4: The standard curve produced from the hydroxyproline assay 
The equation obtained from the standard curve can be applied to the absorbance obtained for the collagen 
stock solution to calculate the amount of hydroxyproline in the collagen stock solution: 
Y = 0.1203X + 0.0277 
(Y÷0.1203) - 0.0277 = X 
(0.122÷0.1203) - 0.0277 = 0.9864µg/ml of hydroxyproline 
Neuman and Logan (1950) presented that the collagen content can be determined by multiplying the 
hydroxyproline content of a sample by 7.46 because the hydroxyproline content of collagen 
in most mammals is 13.5% (100 ÷ 13.5% = 7.4): 
0.9864 x 7.46 = 7.358544 µg/ml collagen 
 
 18 
The collagen solution was predicted to be 7.358544µg/ml, which was lower than 
expected. To validate this result a collagen precipitation reaction was conducted which 
estimated the mean collagen concentration of the solution to be 33.339 mg/ml Collagen. 
Weighing the collagen precipitate is a crude method for determining the concentration of 
solutions. But this measurement is closer to the expected concentration than the 
hydroxyproline results, as collagen gels would not set at such a low concentration. For this 
reason the collagen solution was considered to be 33.339 mg/ml and the percentage of 
collagen per gel was calculated. The gels for testing the effect of collagen concentration 
were calculated to be 1% and 2% collagen gels, whilst the gels for testing the effect of gel 
thickness were calculated to be 1.3%. 
 
Cell Survival 
It was important to confirm the viability of the entrapped BMSCs over time to determine 
whether the collagen gels were capable of maintaining viable BMSCs or whether one 
condition was better than another (figure 5). The vast majority of the BMSCs entrapped 
within the collagen remained viable after 14 days in all the experimental conditions. 
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Figure 5: Live dead assay results for the cells after 14 days of being entrapped within a collagen gel 
Representative images have been included in this figure for each of the different gel conditions. The live cells 
have been stained green with Calcein-AM and the dead cells have been stained red with PI. Each figure 
contains a 10μM scale bar. 
A) A control group containing dead cells to verify the activity of PI 
B) A gel containing no cells to control for background fluorescence 
C) 1% Collagen gel 
D) 2% Collagen gel 
E) Thin (1.3%) collagen gel 
F) Thick (1.3%) collagen gel 
A B 
C D 
F E 
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Discussion 
The assays to quantify the concentration of collagen solutions demonstrate the need for 
further optimisation of the hydroxyproline assay. It is possible that the efficiency could be 
improved through the use of new reagents. For example if the calorimetric reagent, 
chloramine-T, has degraded the reaction efficiency could have been lowered due to the 
breakdown of chloramine-T to form hypochlorite. 
Despite the inefficiency of the hydroxyproline assay, the results presented in this 
paper represent the successful setup and optimisation preliminary stages of an investigation. 
The protocols described in this could form the basis of further work to investigate whether 
changes to the extracellular matrix can stimulate the differentiation of BMSCs along specific 
lineages. The author believes that it would be interesting to explore whether BMSCs in 
entrapped dense collagen gels would preferentially differentiate in cells involved in bone 
formation. Furthermore, to explore whether BMSCs entrapped in low density collagen gels 
would preferentially differentiate in cells involved in adipose tissue formation. 
As the properties of the extracellular matrix would be the variable factor if this 
project were to be continued, the differences between the different types of collagen gels 
must be characterised. This could be conducted using electron-microscopy to estimate the 
pore sizes within the collagen gels. It is expected that gels with a higher collagen 
concentration would have lower pore sizes than gels with lower collagen concentrations. 
Additionally rheology could be conducted to determine the mechanical strength of the gels. 
This testing could be used to determine whether the higher concentration of collagen results 
in greater crosslinking between the collagen molecules. The exact thickness of the collagen 
gels would also be determined. 
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Once the physical properties of the collagen gels had been quantified testing could 
be conducted to determine whether extracellular matrix modulation affects the BMSCs. In 
the first instance reverse transcription quantitative real time PCR (qPCR) could be conducted 
to assess specific changes in the transcriptome of the BMSCs relative to a house keeping 
gene such as GAPDH. It would be interesting to determine whether the entrapped cells have 
properties associated with a variety of markers including, but not limited to: 
Proliferation  - Proliferating Nuclear Cell Antigen (PNCA)  
Quiescence  - P53 
Tissue Remodelling  - Matrix metalloproteinase-1 
BMSC characteristics - Nucleostemin 
- C90/Thy1 
Osteoblast Lineage - Collagen type 1 α1 
- Bone Specific Protein 
Adipocyte Lineage - Adipocyte fatty acid-binding protein 2 
Chondrocyte Lineage - SOX9 
 Further studies at the RNA level could include the use of whole genome microarray 
technology to gain a full picture of the transcriptional changes occurring when BMSCs are 
exposed to extracellular matrix modulation. However this would be expensive and should 
only be used if significant changes have occurred within the cells, with respect to 
differentiation down a specific lineage. 
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 Any results from the qPCR or microarray data could be confirmed using cell staining 
techniques such as the 5-bromo-2'-deoxyuridine (BrdU) proliferation assay (Roche, UK) or Von 
Kossa staining to detect mineralised cells such as those associated with bone and cartilage. 
Furthermore osteoblastic differentiation can be confirmed using energy-dispersive X-ray 
microanalysis to detect the calcium microcrystals synthesized by osteoblasts (George et al., 
2006; Leong, 2010) 
 Should this project be successful these techniques could be applied to explore the 
effects of different types of extracellular matrix on BMSCs. For example there are many 
types of collagen, which are associated with a wide variety of tissues. It would be interesting 
to determine whether BMSCs would preferentially differentiation into chondrocytes when 
exposed to collagen types II, IX, X or XI. All of which are associated with the structural 
composition of cartilage. Furthermore the construction of different layers of types of 
collagen could prove to be useful in creating grafts containing different functional tissues. 
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Conclusion 
Tissue engineering could potentially progress and present a viable alternative to 
transplantation. The implanted tissues could be constructed using synthetic or organic 
materials which can be grown after implantation into the required functionality. 
Alternatively these tissues could be engineered in vitro to form functional organs or tissues 
prior to implantation. 
The type 1 collagen gels developed during this project are capable of supporting the 
viability of BMSCs. The protocols described in this thesis could form the basis for further 
study to explore the possibility producing scaffolds constructed with collagen gels of 
different properties and seeded with undifferentiated BMSCs to produce grafts comprising 
different layers of tissue. The grafts could be grown functional tissues in vitro or directly 
implanted whereby the graft would grow into the required functionality. These collagen gels 
are particularly suitable for the purpose of craniofacial regeneration not only because of 
their possible modulatory properties, but also their physical properties. Collagen gels are 
biocompatibility and have low immunogenicity properties. Furthermore collagen can be 
biodegraded by the body naturally; this means that graft can support the full incorporation 
of the graft into the host body. The host blood vessels would also be able to invade the graft 
to aid graft survivability. The honeycomb nature of the collagen gel provides a platform for 
the exchange of nutrients. Collagen gels can be created to imitate the structure of many 
tissue types and is capable of maintaining its structure without deforming or collapsing 
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Appendix 
Semi-Quantitative PCR 
Semi quantitative PCR was conducted according to the following methods in an attempt to 
gain some preliminary results on the effects of 3-D extracellular matrix modulation. This 
portion of work was not completed due to persistent contamination in the negative control 
and possible non-specific binding or amplification of primer dimers during the 
Glyceraldehyde 3 phosphate dehydrogenase (GAPDH) normalisation process. 
Methods 
RNA Isolation 
Materials Source 
PureLink™ RNA Mini Kit Ambion, UK 
2-mercaptoethanol Sigma-Aldrich, UK 
70% ethanol (in RNase-free water) n/a 
18 gauge syringe needles n/a 
 
Method: 
The BMSCs were lysed by passing the cells 5-10 times through an 18 gauge syringe needle. RNA was 
purified from the lysate using the RNeasy mini kit (including the optional DNase step) according to 
the manufacturer’s instructions. 
 
Generation of cDNA 
Materials Source 
Omniscript RT Kit Qiagen, UK 
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Method: 
The Omniscript RT Kit was used to generate total complementary cDNA from the isolated RNA 
according to the manufacturer’s instructions.  
Normalising cDNA using GAPDH 
Materials Source 
REDTaq Ambion, UK 
Forward and Reverse primers Invitrogen, UK 
cDNA n/a 
RNase free water n/a 
PCR Thermal Cycler 
500 WMastercycler® Family 
Eppendorf, UK 
Agarose for electrophoresis Sigma-Aldrich, UK 
GelRed™ Biotium, UK 
PCR Ranger 100 bp DNA Ladder Norgen, UK 
Electrophoresis tank n/a 
 
 
Primers Sequence 
GAPDH Forward Primer 5’ - CGA TCC CGC TAA CAT CAA AT 
GAPDH Reverse Primer 5’ - GGA TGC AGG GAT GAT GTT CT 
 
A REDTaq master mix made up by adding the following components: 
 
 
 
 
 
Volume (µl) Reagent 
125 REDTaq 
2 Forward and reverse primer mix (10µM) 
<2 cDNA 
25 - all of the above RNase free water 
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For the first PCR reaction each tube contained 1.5µL of cDNA and 23.5µL of the REDTaq master mix. 
6µL was removed after 30 and 40 cycles of the following PCR program: 
94°C - 2 Minutes 
94°C - 30 seconds 
60°C - 20 Seconds 
68°C -30 Seconds 
72°C -2 Minutes 
 
A 1.5% agarose gel gel was made in 1x TAE buffer and 5µL of GelRed was added to the cooled gel 
before pouring. An 18 well comb was required. 6µL of PCR products and the PCR Ranger were loaded 
into the gel and ran for approximately half hour at 120 volts. 
 
Semi quantification PCR bands 
Materials Source 
Genesnap software Syngene, UK 
Gene Tool software Syngene, UK 
 
Images of the gels were taken using genesnap software and Gene Tool software was used to 
determine the intensity of the PCR product bands. These figures were used determine the amount of 
cDNA to use in the next PCR reaction. 
 
PCR Cycles 
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Results 
Well layouts: 
N - Negative Control 
MW - PCR Ranger 
1 - Freshly isolated BMSCs  
2 - P1 BMSCs 
3 - BMSCs after 7 days exposure to dexamethasone 
4 - BMSCs after 2 days within Thick Gels  10 - BMSCs after 2 days within 2% Gels 
5 - BMSCs after 2 days within Thin Gels  11 - BMSCs after 2 days within 1% Gels 
6 - BMSCs after 7 days within Thick Gels  12 - BMSCs after 7 days within 2% Gels 
7 -BMSCs after 7 days within Thin Gels  13 - BMSCs after 7 days within 1% Gels 
8 - BMSCs after 14 days within Thick Gels  14 - BMSCs after 14 days within 2% Gels 
9 -BMSCs after 14 days within Thin Gels  15 - BMSCs after 14 days within 1% Gels 
 
 
 
GAPDH normalisation 1 - PCR after 30 cycles (section a) and 40 cycles (section B) 
The weakest bands could be visualised more easily at higher cycles, but so could undesired products. 
Therefore all further PCR programs utilised 35 cycles. 
Gel Section A 
Gel Section A 
 M   1    2    3   4    5   6   7    8   9   10 11  12 13 14 15   N   M 
 30 
  
GAPDH normalisation 2 
 
GAPDH normalisation 3 
 
 M   1     2      3    4      5     6      7    8     9     10   11   12  13   14   15     N    
 1     2     3    4      5     6      7     8     9    10   11   12  13   14    15    M   N 
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GAPDH normalisation 4 
 
GAPDH normalisation 5 
 
 1     2     3    4      5     6      7     8     9    10   11   12  13   14   15     N   M 
 1     2     3    4      5     6      7     8     9    10   11   12  13   14   15     N   M 
